{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:40:58Z","timestamp":1768995658985,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.contraception.2011.03.024","type":"journal-article","created":{"date-parts":[[2011,6,2]],"date-time":"2011-06-02T11:13:36Z","timestamp":1307013216000},"page":"390-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women"],"prefix":"10.1016","volume":"84","author":[{"given":"Georg A.K.","family":"Schramm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Schrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.03.024_bb0005","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.03.024_bb0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.03.024_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case\u2013control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2011.03.024_bb0020","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.03.024_bb0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara\u00ae). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.contraception.2011.03.024_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive (Belara\u00ae): efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.03.014","article-title":"Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study","volume":"76","author":"Schramm","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0045","first-page":"8","article-title":"Influence of chlormadinone acetate on dysmenorrhoea and other cycle related complaints","volume":"219\u201325","author":"Bock","year":"2008","journal-title":"Gyne"},{"key":"10.1016\/j.contraception.2011.03.024_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11532910-000000000-00000","article-title":"Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study","volume":"30","author":"Anthuber","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2011.03.024_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.contraception.2009.06.011","article-title":"Efficacy of the low-dose combined oral contraceptive chlormadinone acetate\/ethinylestradiol: physical and emotional benefits","volume":"81","author":"Heskamp","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0060","series-title":"Gynakologische Endokrinologie","first-page":"412","author":"Runnebaum","year":"1994"},{"key":"10.1016\/j.contraception.2011.03.024_bb0065","first-page":"1034","article-title":"Advisory board for the new progestin. Evaluation of a new generation of oral contraceptives","volume":"81","author":"Speroff","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/00016349009156503","article-title":"Efficacy and clinical profile of a new oral contraceptive containing norgestimate","volume":"152","author":"Corson","year":"1990","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2011.03.024_bb0075","doi-asserted-by":"crossref","first-page":"263.e1","DOI":"10.1016\/j.ajog.2009.03.017","article-title":"Oral contraceptive effectiveness according to body mass index, weight, age, and other factors","volume":"201","author":"Dinger","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.contraception.2007.12.009","article-title":"Trends in prescribing patterns of hormonal contraceptives for adolescents","volume":"77","author":"O'Brien","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.03.024_bb0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/01443619509015499","article-title":"The risk of venous thromboembolism associated with low-dose estrogen oral contraceptives","volume":"15","author":"Farmer","year":"1995","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2125.2000.00198.x","article-title":"A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives","volume":"49","author":"Farmer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00148581-200608010-00003","article-title":"Hormonal contraception in adolescents: special considerations","volume":"8","author":"Ornstein","year":"2006","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.contraception.2011.03.024_bb0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.03.024_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive (Belara\u00ae)","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2165\/00002018-200427130-00003","article-title":"Safety of a new oral contraceptive containing drospirenone","volume":"27","author":"Heinemann","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2011.03.024_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.contraception.2005.06.068","article-title":"Yasmin Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days","volume":"73","author":"Foidart","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0135","first-page":"275","article-title":"Combination oral contraceptives","volume":"6","author":"Rebar","year":"1997","journal-title":"Curr Ther Endocrinol Metab"},{"key":"10.1016\/j.contraception.2011.03.024_bb0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0010-7824(93)90020-8","article-title":"A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives","volume":"4","author":"Dunson","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.03.024_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0010-7824(94)00010-T","article-title":"Twelve years of clinical experience with an oral contraceptive containing 30 \u03bcg ethinylestradiol and 150 \u03bcg desogestrel","volume":"51","author":"Fotherby","year":"1995","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:09:34Z","timestamp":1762117774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0010782411001569"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.03.024","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}